Format

Send to

Choose Destination
Cell Death Dis. 2019 Oct 7;10(10):758. doi: 10.1038/s41419-019-1994-2.

Progranulin attenuates liver fibrosis by downregulating the inflammatory response.

Author information

1
Environmental Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
2
Industrial Bio-Materials Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
3
Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Republic of Korea.
4
Center for Theragnosis, Korea Institute of Science and Technology, Seoul, 02792, Korea.
5
Incepta Vaccine Limited, Dhamrai, Kalampur, Dhaka, 1351, Bangladesh.
6
Aging Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Korea.
7
National Primate Resources Center, Korea Research Institute of Bioscience and Biotechnology, Jeonbuk, 56212, Republic of Korea. kimjs@kribb.re.kr.
8
Department of Medicinal Biotechnology, College of Health Sciences, Dong-A University, Busan, 49315, Republic of Korea. cvaccine@dau.ac.kr.

Abstract

Progranulin (PGRN) is a cysteine-rich secreted protein expressed in endothelial cells, immune cells, neurons, and adipocytes. It was first identified for its growth factor-like properties, being implicated in tissue remodeling, development, inflammation, and protein homeostasis. However, these findings are controversial, and the role of PGRN in liver disease remains unknown. In the current study, we examined the effect of PGRN in two different models of chronic liver disease, methionine-choline-deficient diet (MCD)-induced non-alcoholic steatohepatitis (NASH) and carbon tetrachloride (CCl4)-induced liver fibrosis. To induce long-term expression of PGRN, PGRN-expressing adenovirus was delivered via injection into the tibialis anterior. In the CCl4-induced fibrosis model, PGRN showed protective effects against hepatic injury, inflammation, and fibrosis via inhibition of nuclear transcription factor kappa B (NF-κB) phosphorylation. PGRN also decreased lipid accumulation and inhibited pro-inflammatory cytokine production and fibrosis in the MCD-induced NASH model. In vitro treatment of primary macrophages and Raw 264.7 cells with conditioned media from hepatocytes pre-treated with PGRN prior to stimulation with tumor necrosis factor (TNF)-α or palmitate decreased their expression of pro-inflammatory genes. Furthermore, PGRN suppressed inflammatory and fibrotic gene expression in a cell culture model of hepatocyte injury and primary stellate cell activation. These observations increase our understanding of the role of PGRN in liver injury and suggest PGRN delivery as a potential therapeutic strategy in chronic inflammatory liver disease.

PMID:
31591383
DOI:
10.1038/s41419-019-1994-2
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center